German biotechnology company BioNTech SE (Nasdaq:BNTX), the development partner with Pfizer for a COVID-19 vaccine, on 24 September 2020 joined other leading COVID-19 vaccine developers in ruling out participation in Britain's plans to test experimental inoculations by deliberately infecting trial volunteers.
According to a spokesman of the company, "BioNTech's vaccine candidate is not part of this study."
Britain said it was working with partners on the potential for human challenge trials without commenting on a specific plan.
AstraZeneca and Sanofi both have said their vaccine candidates were not involved in the programme, Reuters added.
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine
TransCode acquires Polynoma and secures USD25m investment from CK Life Sciences
Wasatch BioLabs adds three Oxford Nanopore-developed research-use-only assays to service portfolio